Browse Category

Investment News 22 December 2025

Shriram Finance Share Price Hits Record High on MUFG’s $4.4 Billion Stake Deal: Latest News, Analyst Targets, and Stock Outlook (Dec 22, 2025)

Shriram Finance Share Price Hits Record High on MUFG’s $4.4 Billion Stake Deal: Latest News, Analyst Targets, and Stock Outlook (Dec 22, 2025)

Shriram Finance Ltd (NSE: SHRIRAMFIN, BSE: 511218) is in the spotlight on December 22, 2025, after its stock jumped to fresh record highs on the back of a landmark strategic investment by Japan’s Mitsubishi UFJ Financial Group (MUFG). The deal—structured
22 December 2025
Singtel Stock (SGX: Z74) in Focus on Dec. 22, 2025: Share Price, Optus Updates, Analyst Forecasts and 2026 Catalysts

Singtel Stock (SGX: Z74) in Focus on Dec. 22, 2025: Share Price, Optus Updates, Analyst Forecasts and 2026 Catalysts

SINGAPORE (Dec. 22, 2025) — Singapore Telecommunications Limited (Singtel) stock is trading around S$4.55 on Monday afternoon, with investors balancing two competing narratives: the steadiness of a cash-generative telecom and the ongoing operational/regulatory headlines tied to subsidiary Optus—against the increasingly
22 December 2025
Ashok Leyland Share Price Hits All-Time High as Nomura Raises Target to ₹196; Traders Track Key Levels in Revathi Equipment

Ashok Leyland Share Price Hits All-Time High as Nomura Raises Target to ₹196; Traders Track Key Levels in Revathi Equipment

New Delhi / Mumbai, December 22, 2025: India’s stock market entered the week with a cautiously positive tone, with traders watching the Nifty’s 26,000 resistance while tracking sector-specific momentum. In the spotlight on Monday, December 22, 2025, was Ashok Leyland
CSL Limited (ASX:CSL) Stock Update: Share Price, Buyback Progress, Analyst Forecasts and Key Catalysts as of 22 December 2025

CSL Limited (ASX:CSL) Stock Update: Share Price, Buyback Progress, Analyst Forecasts and Key Catalysts as of 22 December 2025

CSL Limited shares were trading around A$176 on 22 December 2025, modestly higher on the session but still nursing a steep 2025 decline that has kept the biotech heavyweight under intense investor scrutiny heading into 2026. Investing.com+2MarketWatch+2 The story around
1 7 8 9 10 11 90
Go toTop